Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (191-200 of 768) with videos related to

Pageof 77
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|August 3, 2017
Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive reviewAlan L Myers, Jitesh D Kawedia, Richard E Champlin, et al.
Therapeutic Immunology|April 1, 1994
Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantationD Przepiorka, C F LeMaistre, Y O Huh, et al.
Critical Care Medicine|May 16, 2000
Outcome of bone marrow transplantation patients requiring mechanical ventilationA J Huaringa, F J Leyva, S A Giralt, et al.
Bone Marrow Transplantation|February 3, 2004
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokineticsI F Khouri, M Albitar, R M Saliba, et al.
Bone Marrow Transplantation|June 11, 2003
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancerR Wong, G Rondon, R M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2004
Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant RegistryMary Eapen, Mary M Horowitz, John P Klein, et al.
Nature Medicine|September 6, 2000
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemiaJ J Molldrem, P P Lee, C Wang, et al.
Annals of Internal Medicine|February 1, 1993
Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trialD J Winston, W G Ho, K Bartoni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1995
Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myelomaJ E Bayouth, D J Macey, L P Kasi, et al.
Blood Cancer Journal|January 14, 2014
Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell linesB C Valdez, A R Zander, G Song, et al.
Pageof 77

Showing results (191-200 of 768) with videos related to

Sort By:
Pageof 77
Expert Opinion on Drug Metabolism & Toxicology|August 3, 2017
Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive reviewAlan L Myers, Jitesh D Kawedia, Richard E Champlin, et al.
Therapeutic Immunology|April 1, 1994
Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantationD Przepiorka, C F LeMaistre, Y O Huh, et al.
Critical Care Medicine|May 16, 2000
Outcome of bone marrow transplantation patients requiring mechanical ventilationA J Huaringa, F J Leyva, S A Giralt, et al.
Bone Marrow Transplantation|February 3, 2004
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokineticsI F Khouri, M Albitar, R M Saliba, et al.
Bone Marrow Transplantation|June 11, 2003
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancerR Wong, G Rondon, R M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2004
Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant RegistryMary Eapen, Mary M Horowitz, John P Klein, et al.
Nature Medicine|September 6, 2000
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemiaJ J Molldrem, P P Lee, C Wang, et al.
Annals of Internal Medicine|February 1, 1993
Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trialD J Winston, W G Ho, K Bartoni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1995
Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myelomaJ E Bayouth, D J Macey, L P Kasi, et al.
Blood Cancer Journal|January 14, 2014
Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell linesB C Valdez, A R Zander, G Song, et al.
Pageof 77